Company profile
Advancing Innovative Therapies | Committed to leadership in resolving serious, unmet medical needs for the betterment of overall human health
We are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNzAyNjU1NmFkaXF6a2N4 | Paper/PDF filed
Published 29 Sep 2024 05:48
Company registered at Companies House
1 Jan 2017 to 31 Dec 2018
We need new classes of antibiotics because multi-drug resistant (MDR) bacteria are threatening our ability to treat infectious disease. The UK government estimates that without new antibiotics infectious disease will cost the global economy $100 trillion by 2050. Discuva’s innovative (and proprietary) technology (SATIN) is a proven platform for the discov...
1 Dec 2012 to 31 May 2015
Discuva’s technology provides a powerful platform to discover new classes of antibiotics which have major advantages over conventional antibiotics; reduced development of resistance, fewer side effects and longer market life. Small molecule antibiotics are first identified by high-throughput phenotypic screening of specialised compound collections. The ro...
